Joined in 2023 
82 
63 About this deal
Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytother Res. 2006 Oct;20(10):859–64. DOI: 10.1002/ptr.1953. PMID: 16835878.
Modified Citrus Pectin BenefitsConners Clinic | Alternative
This was actually a large dose, so the fact that it was tolerated well by children is encouraging. The dose of MCP used in this study was equivalent to one scoop of Pectasol-C modified citrus pectin three-times daily for three months. (In our practice, we treat adults with one scoop twice daily for between 45 and 90 days, which we have found effective at lowering serum lead levels.) Slowing Heart Disease In the US, the researched form of MCP is patented for structure-function health claims related to cellular, cardiovascular and immune health, as well as inflammation, fibrosis and toxic metal body burden. But the loss of important minerals may not occur with use of modified citrus pectin, as evidenced by a recent study on urinary excretion of toxic elements in healthy individuals.
Azémar M, Hildenbrand B, Haering B, Heim ME, Unger C. Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study. Clin Med Oncol. 2007 Jan;1:CMO.S285. DOI: 10.4137/CMO.S285.
PectaSol-C (Modified Citrus Pectin) 270 Capsules - Natures Fix
We now understand that as a culprit biomarker, extracellular Gal-3 functions as a key driver behind the development and progression of metastatic cancer, cardiovascular disease, organ fibrosis, neurodegenerative disease, immune dysregulation, premature ageing and many other conditions. Published in 2006, a study demonstrated PectaSol-C MCP's ability to bind and remove toxic heavy metals from the body, without affecting essential minerals. Heavy metal removal with PectaSol-C MCP has been shown in multiple case studies to play a role in ongoing body maintenance. P.P. Ruvolo, “Galectin-3 as a Guardian of the Tumor Microenvironment,” Biochim. Biophys. Acta. 1863(3), 427–437 (2016). Suppressed the viability in MDA-MB-231, MCF-7 and T47D human Breast cancer cells, ↓ mRNA expression of galectin-3BMDM were isolated following a standard protocol [ 11]. In brief, femur and tibia bones are collected from C57BL6/J mice and bone marrow cells were flushed out using red blood cell lysis buffer. Then BMDM cells are cultured in BMDM growth medium (RPMI-1640 supplemented with 10% FBS, 50 ng M-CSF) for 7 days. Cell viability assay The original and only proven effective form of MCP is prepared with a proprietary, non-GMO enzymatic process controlled by pH and heat, which breaks the long chain molecules of the native pectin to produce the correct molecular size and structure of <13 kilodaltons and <5% esterification. C. Ramachandran, et al., “Synergistic Antioxidant and Anti-Inflammatory Effects Between Modified Citrus Pectin and Honokiol,” Evid. Based Complement Alternat. Med. doi: 10.1155/2017/8379843 (2017).
Abstract 4918: Modified citrus pectin slows migration of
More than 50 published clinical and preclinical studies on this form of MCP demonstrate its critical, multifaceted benefits against heart disease, cancer proliferation/metastasis, organ fibrosis and other conditions characterised by elevated Gal-3. Nearly 1.7 million new cases of breast cancer arise annually worldwide, accounting for 25.2% of all cancer cases (WHO). Approximately 15% of breast cancer patients die following diagnosis, second only to lung cancer [ 10, 11]. Complex, molecular breast cancer occurs when gene mutations cause abnormal cell growth and proliferation [ 12]. In vitro and in vivo studies have shown that pectin-derived chemicals slow cell development and promote apoptosis [ 13]. The synergistic and additive effects of MCP have been studied in human breast cancer cells. Polybotanical compounds BreastDefend (BD) or ProstaCaid (PC) used in combination with MCP reduced the invasive potential of highly metastatic human breast cancer MDA-MB-231 cells. MCP may also prevent the development of human breast cancer in mice by reducing angiogenesis, a crucial mechanism for tumor growth. The α-galactosidase binding protein Gal-3 is one potential mediator of MCP’s inhibition of breast and prostate cancer cell adhesion, migration, and invasion [ 7]. MCP inhibits urokinase-type plasminogen activator (uPA) synthesis in breast and prostate cancer cells, and the uPA receptor (uPAR) regulates cell adhesion, migration, and invasion [ 14]. In addition to activating macrophages, CP decreased activator protein 1 (AP-1) and NF-κB signaling but increased LPS/Toll-like receptor 4 (TLR-4) signaling [ 15]. In another study, CP and apple pectin (AP) inhibited MDA-MB-231, MCF-7, and T47D breast cancer cells, finding that CP and AP inhibited cancer cells in the S and G1 or G2/M phases of the cell cycle. Similarly, the expression of Gal-3, a lectin implicated in cell adhesion, cell cycle, and death, was reduced by CP and AP. In addition, oxidative and strand-break DNA damage was observed in MDA-MB-231 cells, slowing proliferation [ 16]. PectaSol-C is a natural product derived from the pith of citrus fruit, and modified to meet scientifically proven molecular weight and structure characteristics. This product is recognized for its ability to promote cell growth and proliferation. Z.Y. Zhao, et al., “The Role of Modified Citrus Pectin as an Effective Chelator of Lead in Children Hospitalized with Toxic Lead Levels,” Altern. Ther. Health Med. 14(4), 34–38 (2008).
From this extensive body of published literature, only one available natural agent has emerged to demonstrate the singular ability to halt and reverse the harmful effects of Gal-3: a specific form of the nutraceutical ingredient modified citrus pectin (MCP) that’s derived from citrus peel pith and enzymatically modified to precise low molecular specifications for efficacy and bioactivity (PectaSol-C). F. Sanchis-Gomar, et al., “Galectin-3, Osteopontin and Successful Aging,” Clin. Chem. Lab. Med. 54(5), 873–877 (2016).
Pectin: A Bioactive Food Polysaccharide with Cancer
Galectin-3 seems to be a target of MCP. Galectin-3 protein can be found intra- and extracellularly and contains a lectin domain. It has pleiotropic functions, amongst which, it mediates cell-cell as well as cell-extracellular matrix adhesion, through binding to glycoconjugates. Indeed, this lectin-domain has a high affinity for ß-galactoside residues. Galectin-3 expression is dysregulated in transformed cells, being highly expressed in numerous different types of cancer cells ( Newlaczyl and Yu, 2011). MCP has been shown to decrease liver metastasis in a mouse colon cancer model, in a dose-dependent manner. This effect may be linked to the higher expression of galactin-3 in the liver metastases ( Liu et al., 2008). The relationship between MCP structure and its inhibitory activity on galectin-3 was investigated in several studies. One such example is the work by Sathisha et al. (2007) who compared the activation of pectins from different dietary plants. Pectins rich in galactose and arabinose and in arabinogalactan significantly inhibited galectin-3-dependent hemagglutination of MDA-MB-231 cells to erythrocytes ( Sathisha et al., 2007). Pectin nearly mainly composed of RG-I isolated from okra, a tropical plant, arrested cell cycle of B16F10 cells in G2/M phase and induced apoptosis probably through interaction with galectin-3 ( Vayssade et al., 2010). Gao et al. (2012) suggested that MCP ability to inhibit galectin-3 resides in its RG-I regions and more particularly from galactan, of which the nature of last residue is the most important. Gunning et al. (2013) confirmed that neutral galactan side chains did selectively bind to recombinant galectin-3. These active fragments can be obtained by enzymatic treatment of isolated RG-I regions from potato pectin ( Gunning et al., 2009). This MCP is also shown to increase the effectiveness of radiotherapy and to synergise with two polybotanical anticancer formulas for breast and prostate cancer. 15,16 MCP in combination with a purified botanical extract from magnolia bark, honokiol (protected by US Patent No. 8916541 and European Patent EP2661173B1), has also shown synergy for antioxidant and anti-inflammatory effects. 17 The mechanical role of RG-I has been less studied but it seems that RG-I may play a role in cell wall plasticity, for example by preventing HG chains to interact with Ca 2 + ions. Transgenic plants with decreased amounts of arabinans and galactans display a stiffening of their cell wall. I. Eliaz, E. Weil and B. Wilk, “Integrative Medicine and the Role of Modified Citrus Pectin/Alginates in Heavy Metal Chelation and Detoxification — Five Case Reports,” Forsch Komplementmed. 14(6), 358–364 (2007). C. Ramachandran, et al., “Activation of Human T-Helper/Inducer Cell, T-Cytotoxic Cell, B-Cell, and Natural Killer (NK)-Cells and Induction of Natural Killer Cell Activity Against K562 Chronic Myeloid Leukemia Cells with Modified Citrus Pectin,” BMC Complement Altern. Med. 11, 59 (2011).Substituted galacturonans make a group of various polysaccharides whose linear chain is composed of D-Gal pA residues linked in α-1,4 (as in HG) and on which are grafted other residues. Among these GS, is rhamnogalacturonan-II (RG-II). RG-II has nothing to do with RG-I, its main chain is not composed of GalA-Rhap disaccharide but of a HG chain. Four types of chains with structurally different oligosaccharides are linked to the main chain of RG-II, they are composed of 12 types of glycosyl residues bound together by at least 22 types of glycosidic bounds. One nonasaccharide (lateral chain B) and one octasaccharide (lateral chain A) are attached in C-2 of some GalA residues from the main chain and two different disaccharides are linked in C-3 of the main chain. The localization of these lateral chains one in relation to the other is not yet determined (Figure 1). RG-II is often found in dimers thanks to a borate ion located on chain A. This dimerisation seems essential for the integrity of the plant cell wall. Despite its complexity, the RG-11 structure is well conserved in vascularized plants. Very few mutants with modified RG-II have been identified until now, which indicates the importance to conserve its structure. Other GS have been described in a short number of plants. Xylogalacturonan contains β- D-xylosyl (Xylp) linked in C3 of the main chain and is present in reproductory tissues of plants like apple, carrot and cotton. Apiogalacturonan contains monomers or dimers of β- D-apioduranosyl (Apif) attached in C-2 and C-3 of the main chain. Apiogalacturonan is found in some monocotyledons ( Ridley et al., 2001; Mohnen, 2008; Caffall and Mohnen, 2009; Harholt et al., 2010; Figure 1).
Great Deal 
New Comment